Cargando…

Blood-based biomarker in Parkinson’s disease: potential for future applications in clinical research and practice

The clinical presentation of Parkinson’s disease (PD) is both complex and heterogeneous, and its precise classification often requires an intensive work-up. The differential diagnosis, assessment of disease progression, evaluation of therapeutic responses, or identification of PD subtypes frequently...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tönges, Lars, Buhmann, Carsten, Klebe, Stephan, Klucken, Jochen, Kwon, Eun Hae, Müller, Thomas, Pedrosa, David J., Schröter, Nils, Riederer, Peter, Lingor, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Vienna 2022
Materias:	Neurology and Preclinical Neurological Studies - Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463345/ https://www.ncbi.nlm.nih.gov/pubmed/35428925 http://dx.doi.org/10.1007/s00702-022-02498-1

Ejemplares similares

Classification of advanced stages of Parkinson’s disease: translation into stratified treatments
por: Krüger, Rejko, et al.
Publicado: (2017)

Significance of clinical symptoms and red flags in early differential diagnosis of Parkinson’s disease and atypical Parkinsonian syndromes
por: Schröter, Nils, et al.
Publicado: (2023)

The heterogeneity of Parkinson’s disease
por: Wüllner, Ullrich, et al.
Publicado: (2023)

Blood neurofilament light chain in Parkinson’s disease
por: Buhmann, Carsten, et al.
Publicado: (2023)

Monogenetic Forms of Parkinson’s Disease – Bridging the Gap Between Genetics and Biomarkers
por: Tönges, Lars, et al.
Publicado: (2022)

Brainstem Raphe Alterations in TCS: A Biomarker for Depression and Apathy in Parkinson's Disease Patients
por: Richter, Daniel, et al.
Publicado: (2018)

Data-driven subtyping of Parkinson’s disease: comparison of current methodologies and application to the Bochum PNS cohort
por: Chen, Qiang, et al.
Publicado: (2023)

Implications of dopaminergic medication withdrawal in Parkinson’s disease
por: Koschel, J., et al.
Publicado: (2021)

The Diagnostic Scope of Sensor-Based Gait Analysis in Atypical Parkinsonism: Further Observations
por: Gaßner, Heiko, et al.
Publicado: (2019)

L-DOPA-therapy in Parkinson’s disease: some personal reflections on L-DOPA therapy from Vienna and Berlin
por: Riederer, Peter, et al.
Publicado: (2023)

Parkinson’s disease therapy: what lies ahead?
por: Wolff, Andreas, et al.
Publicado: (2023)

Serum neurofilament light chain and postural instability/gait difficulty (PIGD) subtypes of Parkinson’s disease in the MARK-PD study
por: Pötter-Nerger, Monika, et al.
Publicado: (2022)

Iron as the concert master in the pathogenic orchestra playing in sporadic Parkinson’s disease
por: Riederer, P., et al.
Publicado: (2021)

Viruses, parkinsonism and Parkinson’s disease: the past, present and future
por: Leta, Valentina, et al.
Publicado: (2022)

Lewy bodies, iron, inflammation and neuromelanin: pathological aspects underlying Parkinson’s disease
por: Riederer, Peter, et al.
Publicado: (2023)

Shared cerebral metabolic pathology in non-transgenic animal models of Alzheimer's and Parkinson's disease
por: Barilar, Jelena Osmanovic, et al.
Publicado: (2020)

Best practice approaches to outpatient management of people living with Parkinson’s disease during the COVID-19 pandemic
por: Demleitner, Antonia F., et al.
Publicado: (2022)

Plasma autoantibodies to glial fibrillary acidic protein (GFAP) react with brain areas according to Braak staging of Parkinson’s disease
por: Gschmack, Eva, et al.
Publicado: (2022)

Discussing sexuality with Parkinson’s disease patients: a multinational survey among neurologists
por: de Rooy, F. B. B., et al.
Publicado: (2019)

The role of tyrosine hydroxylase as a key player in neuromelanin synthesis and the association of neuromelanin with Parkinson’s disease
por: Nagatsu, Toshiharu, et al.
Publicado: (2023)

Leveraging the Potential of Digital Technology for Better Individualized Treatment of Parkinson's Disease
por: Fröhlich, Holger, et al.
Publicado: (2022)

Diagnostic biomarkers for Parkinson’s disease at a glance: where are we?
por: Cova, Ilaria, et al.
Publicado: (2018)

Editorial: Biomarkers of non-motor symptoms in Parkinson's disease and parkinsonisms
por: Filippi, Massimo, et al.
Publicado: (2023)

SARS-CoV-2 and neurodegenerative diseases: what we know and what we don’t
por: Lingor, Paul, et al.
Publicado: (2022)

Coronaviruses: a challenge of today and a call for extended human postmortem brain analyses
por: Riederer, Peter, et al.
Publicado: (2020)

Non-lesional treatment options for tremor in idiopathic Parkinson syndrome: a protocol for a systematic literature review
por: Pedrosa Carrasco, Anna Julia, et al.
Publicado: (2021)

Missing heritability in Parkinson’s disease: the emerging role of non-coding genetic variation
por: Ohnmacht, Jochen, et al.
Publicado: (2020)

Chorea-Acanthocytosis Presenting as Autosomal Recessive Epilepsy in a Family With a Novel VPS13A Mutation
por: Weber, Juliane, et al.
Publicado: (2019)

The Parkinson’s disease waiting room of the future: measurements, not magazines
por: Alberts, Jay L., et al.
Publicado: (2023)

Biomarkers for Dementia, Fatigue, and Depression in Parkinson's Disease
por: Prell, Tino, et al.
Publicado: (2019)

Levodopa improves handwriting and instrumental tasks in previously treated patients with Parkinson’s disease
por: Müller, Thomas, et al.
Publicado: (2020)

Sex Disparities in the Self-Evaluation of Subthalamic Deep Brain Stimulation Effects on Mood and Personality in Parkinson's Disease Patients
por: Dietrich, Amelie D., et al.
Publicado: (2020)

Amantadine: reappraisal of the timeless diamond—target updates and novel therapeutic potentials
por: Danysz, Wojciech, et al.
Publicado: (2021)

Future Perspectives on the Relevance of Auditory Markers in Prodromal Parkinson's Disease
por: De Groote, Evelien, et al.
Publicado: (2020)

SARS-CoV-2, COVID-19 and Parkinson’s Disease—Many Issues Need to Be Clarified—A Critical Review
por: Goerttler, Tsepo, et al.
Publicado: (2022)

Driving ability and predictors for driving performance in Multiple Sclerosis: A systematic review
por: Seddiq Zai, Susan, et al.
Publicado: (2022)

Perspective: Current Pitfalls in the Search for Future Treatments and Prevention of Parkinson's Disease
por: Poortvliet, Peter C., et al.
Publicado: (2020)

Selegiline: a molecule with innovative potential
por: Tábi, Tamás, et al.
Publicado: (2019)

Recommendations for Standards of Network Care for Patients with Parkinson’s Disease in Germany
por: Prell, Tino, et al.
Publicado: (2020)

Brainstem Encephalitis With Low-Titer Acetylcholine Receptor Antibodies Mimicking Myasthenia Gravis
por: Ayzenberg, Ilya, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kbpbmeeaqppa6uf74diqf4jrv6